Liver fibrosis arises when chronic injury from viral hepatitis, alcohol, fatty liver disease, or other insults pushes hepatic stellate cells into an activated, myofibroblast-like state. In their quiescent form, these cells store vitamin A and quietly regulate blood flow through the liver’s sinusoids. When activated, they proliferate, migrate, and deposit extracellular matrix faster than it can be degraded, gradually choking the organ’s architecture into the stiff, nodular tissue of cirrhosis. Despite decades of research, no approved therapy reverses established fibrosis; treatment has largely meant removing the underlying cause and hoping the liver’s own regenerative capacity keeps pace. Praziquantel had already shown hints of anti-fibrotic activity in experimental settings, but how a drug best known for paralyzing schistosome worms could calm scar-forming liver cells remained a mystery.

To crack that mystery, the research team, led by Zhongkui Lu and Guoying Zhang of Nanjing Integrated Traditional Chinese and Western Medicine Hospital affiliated with Nanjing University of Chinese Medicine, together with colleagues at Xuzhou Medical University and Jinling Hospital, assembled potential praziquantel targets from public pharmacological databases and cross-referenced them against genes implicated in liver fibrosis. The overlap yielded 137 candidate genes. Enrichment analyses of this set pointed toward pathways involving xenobiotic metabolism and neuroactive ligand-receptor interactions, a signature consistent with the drug’s known pharmacology but also hinting at receptor-mediated effects beyond simple parasite membrane disruption.

The next step was to find the critical nodes within this network. Using the STRING database to construct a protein-protein interaction map and Cytoscape to visualize and prune it, the researchers identified six hub genes at the center of the praziquantel-fibrosis intersection: EGFR, ALB, TP53, PTGS2, ESR1, and CYP3A4. These genes span a striking range of functions, from growth factor signaling and tumor suppression to drug metabolism and hormone reception. But which of them actually matters causally for fibrosis, rather than merely being correlated with it? To answer that question, the team turned to Mendelian randomization, a statistical technique that uses naturally occurring genetic variants as instruments to test whether an exposure, here the expression or function of a candidate gene, has a causal effect on an outcome.

The Mendelian randomization analysis delivered a clear verdict for one gene. ESR1, the estrogen receptor alpha gene, showed genetically supported evidence of a protective causal role against liver fibrosis. A colocalization analysis, which tests whether the same genetic variant drives both the gene signal and the disease association in a genomic region, nominated a specific variant, rs3020404, as a plausible functional basis for the link. In other words, the population genetics did not merely suggest that ESR1 expression tracks with fibrosis severity; it suggested that inherited differences in ESR1 activity genuinely shift fibrosis risk, making the receptor a credible therapeutic target rather than a bystander.

Genetic plausibility still needed a physical mechanism, and for that the researchers turned to molecular modeling. Molecular docking placed praziquantel within ESR1’s ligand-binding pocket, and molecular dynamics simulations confirmed that the drug-receptor complex remains stable over simulated time, with the small molecule maintaining consistent contacts with the receptor. The modeling cannot prove binding in a living cell on its own, but it established that praziquantel and ESR1 are chemically compatible partners, setting the stage for functional tests.

The most revealing layer of the study came from single-cell RNA sequencing of liver tissue. Analyzing the data with the Seurat framework, the researchers mapped ESR1 expression across the liver’s cellular ecosystem and found it broadly present, but with a telling pattern: quiescent hepatic stellate cells and a cytokine-producing stellate cell subset, dubbed cyHSCs, expressed significantly higher levels of ESR1 than activated myofibroblastic stellate cells, or myHSCs. The receptor that praziquantel appears to target is most abundant precisely in the cell states that fibrosis threatens to destroy or corrupt, suggesting the drug may act by reinforcing the quiescent, non-fibrogenic identity of these cells.

To probe what ESR1 actually does inside stellate cells, the team ran virtual knockout experiments using scTenifoldKnk, a computational method that predicts how silencing a gene rewires a single-cell gene regulatory network. Removing ESR1 in silico disrupted a network whose most prominent casualties included RXFP1, EGFLAM, and several mitochondrial genome components such as MT-CO1, MT-CO2, and MT-ND4L. Pathway analysis of the perturbed genes showed strong enrichment in oxidative phosphorylation and immune signaling, including T cell receptor signaling. The picture that emerges is of ESR1 as an orchestrator of mitochondrial metabolic homeostasis and immunoregulatory signaling in stellate cells; when it is lost, the cells’ energy metabolism falters and inflammatory programs gain ground, conditions that favor fibrogenic activation.

Computational predictions, however convincing, demand wet-lab confirmation, and the researchers provided it. Working with LX-2 cells, a widely used human hepatic stellate cell line, they silenced ESR1 and tested whether praziquantel could still exert its anti-fibrotic effects. It could not, at least not fully. The loss-of-function experiments confirmed that ESR1 is functionally required for the drug’s benefit, closing the loop between network prediction, genetic causality, structural modeling, and cellular mechanism. The authors propose that praziquantel activates ESR1, which in turn maintains a protective gene network preserving mitochondrial function and immune balance in stellate cells, thereby blocking their transition into collagen-secreting myofibroblasts.

The implications extend well beyond one drug and one receptor. Repurposing praziquantel, whose safety profile is established through mass administration programs across the tropics, could dramatically shorten the path to clinical testing for an anti-fibrotic indication compared with developing a novel molecule from scratch. More broadly, the study showcases an integrative strategy, combining network pharmacology, Mendelian randomization, colocalization, molecular dynamics, single-cell transcriptomics, virtual knockout, and in vitro validation, that can elevate a computational hypothesis to a mechanistically grounded candidate therapy. ESR1 modulation itself may prove a fruitful therapeutic direction independent of praziquantel, and the identification of rs3020404 as a candidate functional variant offers a genetic handle for stratifying patients most likely to benefit. Much work remains: the findings rest heavily on human cell lines and public datasets, and animal models and clinical trials will be needed to confirm that the mechanism operates in scarred livers in living patients. But the study reframes a familiar antiparasitic as a plausible antifibrotic and hands hepatology a genetically validated, druggable target at the heart of the stellate cell’s decision to scar or stay quiet.

Subject of Research: Network pharmacology and experimental validation identifying ESR1 as the target through which praziquantel alleviates liver fibrosis

Article Title: Praziquantel targeting ESR1 to alleviate liver fibrosis: a comprehensive network analysis insight

Article References: Lu, Z., Kong, D., He, F., Lv, H., Guo, Y., Xia, X., & Zhang, G. (2026). Praziquantel targeting ESR1 to alleviate liver fibrosis: a comprehensive network analysis insight. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08941-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08941-1

Keywords: praziquantel, liver fibrosis, ESR1, hepatic stellate cells, Mendelian randomization, molecular docking, single-cell RNA sequencing, drug repurposing, mitochondrial function, hepatology, gene regulatory network, LX-2 cells

The liver’s ability to regenerate after injury is among the most remarkable feats of human biology. Yet, chronic injuries such as those caused by alcohol abuse, metabolic syndromes, and drug-induced toxicity trigger maladaptive repair mechanisms. Hepatic stellate cells, typically quiescent and vitamin A-rich in a healthy environment, become activated upon injury, transforming into myofibroblast-like cells that secrete extracellular matrix (ECM) components excessively. The resulting fibrotic scar tissue stiffens the liver, disrupting its intricate architecture and culminating in irreversible cirrhosis. Although liver transplantation remains the definitive treatment at late disease stages, it is plagued by donor shortages and complex complications, underscoring the urgent need for alternative therapeutic strategies.

Addressing this critical gap, the team at Science Tokyo devised an organoid system, termed iPSC-derived hepatocyte–stellate cell surrounding organoid (iHSO), which recapitulates native liver microenvironments more accurately than previous in vitro models. By differentiating human iPSCs into hepatocyte-like cells (iPS-Heps) and hepatic stellate-like cells (iPS-HSCs), then co-culturing them to form spheroids where stellate cells envelop hepatocytes, the system mimics the liver’s architectural and functional anatomy. This configuration allows direct observation of cellular signaling pathways governing repair and fibrogenesis, a feat impossible in monotypic cultures or animal surrogates.

A pivotal revelation from this model is the dualistic communication between stellate cells and hepatocytes mediated by the adhesion molecule ICAM-1 and cytokine interleukin-1β (IL-1β). The iHSO demonstrated that quiescent iPS-HSCs sustain a cytokine-rich environment that promotes hepatocyte proliferation via the ICAM-1–IL-1β axis, highlighting a supportive stellate cell phenotype in liver regeneration. This intricate signaling relationship elucidates how HSCs can act both as protectors during tissue repair and as drivers of fibrosis when dysregulated, providing critical insights into temporal therapeutic targeting.

Moreover, the iHSO exhibited robust responses to hepatotoxic insult, exemplified by exposure to acetaminophen, a common analgesic known to induce liver injury at high doses. The organoids mirrored pathophysiological injuries seen in vivo, including hepatocyte damage and subsequent stellate cell activation. This injury modeling capacity validates the iHSO as a valuable experimental platform for investigating drug-induced liver injury mechanisms and screening potential hepatoprotective agents, bridging a vital translational gap.

Chronic liver disease constitutes a burgeoning global health crisis, with over four million adults afflicted in the United States alone, and rising incidence rates documented in countries like Japan due to lifestyle and metabolic factors. Despite increased awareness, therapeutic options capable of halting or reversing fibrosis before catastrophic liver failure remain elusive. The human-based iHSO organoid presents a paradigm shift by offering a scalable, physiologically relevant tool for dissecting fibrosis evolution and for accelerating the discovery of anti-fibrotic drugs with greater predictive validity than existing animal models.

Beyond pathological applications, the organoid system opens new avenues in regenerative medicine. Understanding stellate cell heterogeneity — from quiescence to activation states — and their influence on hepatocyte survival and proliferation sets the stage for engineering next-generation bioartificial livers. Such constructs could one day supplement or replace conventional transplants, mitigating immunological rejection risks and donor scarcity.

The research team, led by Professors Sei Kakinuma and Yasuhiro Asahina alongside Assistant Professor Masato Miyoshi and graduate student Tomohiro Mochida, showcases how sophisticated in vitro models can powerfully simulate in vivo biology. Their findings, published in September 2025’s issue of Stem Cell Reports, underscore the transformative potential of organoid platforms in resolving complex cell-to-cell communication pathways essential to liver homeostasis and pathology.

This study not only validates the iHSO as a human-relevant model for liver fibrosis research but also spotlights ICAM-1 and IL-1β as promising molecular targets. Future therapeutic strategies might exploit these pathways to modulate stellate cell behavior, fine-tuning the balance between repair and fibrosis. Such interventions could forestall progression to cirrhosis, reducing the global burden of liver disease and diminishing the reliance on transplantation.

The Institute of Science Tokyo, born from the union of Tokyo Medical and Dental University and Tokyo Institute of Technology, reflects a forward-looking mission to harness fundamental and translational science in advancing human health. With the iHSO model, they have laid a solid foundation for future exploration of hepatic diseases, offering hope that one day, chronic liver injuries will be manageable and even reversible.

In sum, this pioneering organoid system provides a vital, human-based window into the cellular dynamics underlying chronic liver diseases. It redefines experimental possibilities in fibrosis research, opening pathways to innovative drug development and regenerative therapies. As the global community grapples with the rising incidence of liver pathologies, such scientific innovations stand to chart a new course toward addressing one of medicine’s most daunting challenges.

Subject of Research: Cells

Article Title: Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids

News Publication Date: 18-Sep-2025

Web References:
https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)00246-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213671125002462%3Fshowall%3Dtrue

References:
Kakinuma S, Asahina Y, Miyoshi M, Mochida T, et al. Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids. Stem Cell Reports. 2025 Sep 18. DOI: 10.1016/j.stemcr.2025.102642

Image Credits: Institute of Science Tokyo

Keywords: Liver damage, Diseases and disorders, Medical treatments, Clinical medicine, Health and medicine

Pancreatic cancer remains one of the most aggressive malignancies, characterized by late diagnosis and poor prognosis. It is crucial to understand the cellular interactions that facilitate its progression. The study under review illustrates how pancreatic cancer cells communicate with liver cells via extracellular vesicles. These vesicles serve as vehicles for the transfer of bioactive molecules, including microRNAs, which can modulate various cellular functions. This research highlights the significant role that EVs play in establishing a pro-tumorigenic environment in distant organs, particularly the liver.

The exploration of microRNA-25-3p is particularly noteworthy. This small, non-coding RNA has been implicated in various cellular processes, including proliferation, survival, and differentiation. In the context of pancreatic cancer, microRNA-25-3p appears to facilitate the activation of hepatic stellate cells, which are crucial players in liver fibrosis and cancer progression. The activation of HSCs leads to the production of fibrogenic factors, which further enhances the tumor microenvironment conducive to metastasis. Understanding this relationship could unearth potential diagnostic and therapeutic targets.

The methodology employed in this study is robust and thorough. Researchers utilized a combination of in vitro and in vivo models to elucidate the role of microRNA-25-3p in HSC activation. This dual approach ensures that findings are not only relevant in a controlled laboratory environment but also hold true in biological systems. By isolating EVs from pancreatic cancer cell cultures, the study successfully demonstrates that these vesicles are enriched in microRNA-25-3p, establishing a direct link between the cancer cells and HSCs.

Further analysis revealed that treatment of HSCs with EVs containing microRNA-25-3p resulted in enhanced activation markers. This was evidenced by increased expression of α-smooth muscle actin (α-SMA) and collagen production, both of which are indicators of stellate cell activation. The study meticulously quantified these changes, reinforcing the assertion that microRNA-25-3p plays a pivotal role in modulating the behavior of HSCs in response to pancreatic tumor-derived signals.

Equally important is the exploration of the signaling pathways involved in this interaction. The findings suggest that microRNA-25-3p mediates its effects by targeting specific genes responsible for regulating HSC activation. Such insights into the molecular mechanisms at play provide a comprehensive understanding of how pancreatic cancer cells manipulate their environment to favor disease progression. This knowledge could inform the development of novel interventions aimed at disrupting these signaling pathways, potentially arresting cancer spread.

The study’s results have far-reaching implications for the management of pancreatic cancer. Given the limited treatment options available for this aggressive disease, identifying novel biomarkers and therapeutic targets is of utmost importance. MicroRNA-25-3p may serve as a valuable biomarker for early detection or for assessing the aggressiveness of pancreatic tumors. Moreover, targeting EV-associated microRNAs could represent a novel therapeutic strategy that disrupts the communication network between primary tumors and distant tissues.

As the field of cancer research continues to evolve, the focus on the tumor microenvironment and its interactions with systemic host responses is growing. This study contributes significantly to the understanding of how pancreatic cancer orchestrates its environment to thrive and spread. By elucidating the role of microRNAs in this process, researchers open the door to innovative approaches that may improve patient outcomes and survival rates.

Furthermore, the implications of these findings extend to other types of cancers as well. The principles of EV-mediated communication and microRNA-driven modulation of stromal cell activities could be applicable to a diverse array of malignancies. As more studies emerge in this field, it is likely that the understanding of EVs and microRNAs will lead to a paradigm shift in cancer biology, influencing both basic research and clinical practice.

In conclusion, the study of extracellular vesicle-associated microRNA-25-3p marking a significant advancement in the understanding of pancreatic cancer. It not only elucidates the mechanisms by which pancreatic cancer cells engage with hepatic stellate cells but also paves the way for future therapeutic strategies targeting these interactions. With ongoing research, there is a hope that these findings may eventually lead to improved prevention, diagnosis, and treatment modalities for this devastating disease.

This pioneering work is a reminder of the complexity of cancer biology and the importance of continued research in this area. It underscores the need for collaborative efforts across disciplines to unravel the complexities of cancer, aiming for a future where more effective therapies can be developed, ultimately saving lives in the fight against pancreatic cancer.

Explorations into the world of extracellular vesicles and their contents, such as microRNAs, represent a promising frontier in cancer research. As investigations deepen and technology advances, we may soon witness a shift in how we approach cancer therapy, transitioning from a one-size-fits-all mentality to more personalized, targeted strategies based on the molecular signatures of individual tumors. This study serves as a compelling example of how understanding the molecular interplay between tumor cells and their microenvironment can inform new therapeutic opportunities and address critical gaps in current cancer treatments.

Ultimately, this groundbreaking research illustrates that even the smallest molecules can play monumental roles in cancer progression. The potential for microRNA-25-3p and other similar biomolecules to impact treatment paradigms opens exciting avenues for further exploration and innovation in oncology, providing hope for better prospects in managing pancreatic and possibly other cancers in the future.

Subject of Research: Extracellular vesicle-associated microRNA-25-3p in pancreatic cancer progression
Article Title: Extracellular Vesicle-Associated MicroRNA-25-3p Derived from Pancreatic Cancer Cells Promotes Hepatic Stellate Cell Activation and Enhances Cancer Progression
Article References:

Wu, X., Shen, R., Yang, Z. et al. Extracellular Vesicle-Associated MicroRNA-25-3p Derived from Pancreatic Cancer Cells Promotes Hepatic Stellate Cell Activation and Enhances Cancer Progression. Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11186-0

Image Credits: AI Generated
DOI: 10.1007/s10528-025-11186-0
Keywords: MicroRNA-25-3p, extracellular vesicles, pancreatic cancer, hepatic stellate cells, cancer progression